We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prulifloxacin.
- Abstract
Adis Comments Prulifloxacin [NM 441, NAD-441A, Quisnon], the lipophilic prodrug of NM 394 [NAD 394, Sword™], is a novel fluoroquinolone being jointly developed in Japan by Nippon Shinyaku and Meiji Seika (licensee). Prulifloxacin is effective against Gram-positive and -negative bacteria, including Pseudomonas aeruginosa. In clinical studies, the compound has shown good efficacy against respiratory tract and urinary tract infections. Prulifloxacin is awaiting registration for the treatment of urinary tract and respiratory tract infections (Italy and Japan) and bacterial pneumoniae (Japan). Marketing approval was originally applied for in Japan in March 1997. Prulifloxacin has been granted a positive approval recommendation by Japan's advisory Food and Drug's Sanitation Council. The product will be co-marketed with Meiji Seika (as Sword™) in Japan for the treatment of a broad range of infections. Angelini ACRAF SpA is the licensee for the product in Italy, and a Marketing Approval Application (MAA) was filed in Italy in late 1998. Following the approval of prulifloxacin in Italy, further approvals will be sought in other European countries.
- Subjects
ANTISEPTICS; NIPPON Shinyaku Co. Ltd.; MEIJI Seika Pharma Co. Ltd.
- Publication
Drugs in R&D, 2002, Vol 3, Issue 6, p426
- ISSN
1174-5886
- Publication type
Article
- DOI
10.2165/00126839-200203060-00013